Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial.
Maria Di BartolomeoMonica NigerFederica MoranoSalvatore CoralloMaria AntistaStefano TamberiSara LonardiSamantha Di DonatoRossana BerardiMario ScartozziGiovanni Gerardo CardellinoFrancesco Di CostanzoLorenza RimassaAlberto Gianluigi LuporiniRaffaella LongariniAlberto ZaniboniAlessandro BertoliniGianluca TomaselloGraziella PinottiGiorgio ScagliottiGiampaolo TortoraAndrea BonettiAndrea SpallanzaniGiovanni Luca FrassinetiDavide TassinariFrancesco GiulianiSaverio CinieriEvaristo MaielloClaudio VerusioSergio BracardaVincenzo CatalanoMichele BassoLibero CiuffredaFerdinando De VitaHector Soto ParraLorenzo FornaroMarta CaporaleFilippo de BraudFilippo PietrantonioPublished in: BMC cancer (2019)
ARMANI is registered at ClinicalTrials.gov ( NCT02934464 , October 17, 2016) and EudraCT(2016-001783-12, April 202,016).